This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International

Book Now! Early Registration Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Kristin Wolff
Vice President, Access, Value, and Evidence Strategy (AVES) at bluebird bio


Kristin Wolff is the Vice President, Access, Value, and Evidence Strategy (AVES) at bluebird bio, a clinical stage gene therapy company. In this role, Kristin is responsible for developing and executing a holistic market access strategy to achieve timely and meaningful patient access to approved gene therapies in a competitive environment. This approach prioritizes aligning elements across pricing and contracting strategy, HEOR, payer engagement, patient services, and channel/distribution strategy. Prior to joining bluebird, Kristin held roles at the Biotechnology Innovation Organization and the National Academies of Science with portfolios that included Medicare and Medicaid coding, coverage, and reimbursement strategy, science policy, and medical and public health preparedness. Kristin holds a B.A. in Neuroscience from the Johns Hopkins University and an MPH from Dartmouth College.

Agenda Sessions

  • Panel Discussion: Market Access, Pricing and Reimbursement Strategies for Cell and Gene Therapies